Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs.

Autor: Lepper A; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute at the University Medical Centre Mannheim, Mannheim, Germany.; Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Bitsch R; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute at the University Medical Centre Mannheim, Mannheim, Germany.; Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Özbay Kurt FG; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute at the University Medical Centre Mannheim, Mannheim, Germany.; Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Arkhypov I; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute at the University Medical Centre Mannheim, Mannheim, Germany.; Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Lasser S; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute at the University Medical Centre Mannheim, Mannheim, Germany.; Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Utikal J; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute at the University Medical Centre Mannheim, Mannheim, Germany., Umansky V; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute at the University Medical Centre Mannheim, Mannheim, Germany.; Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

Publikováno v: Oncoimmunology [Oncoimmunology] 2023 Aug 13; Vol. 12 (1), pp. 2247303. Date of Electronic Publication: 2023 Aug 13 (Print Publication: 2023).

Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients.

Autor: Petrova V; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute at the University Medical Centre Mannheim, Mannheim, Germany.; Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Groth C; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute at the University Medical Centre Mannheim, Mannheim, Germany.; Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Bitsch R; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute at the University Medical Centre Mannheim, Mannheim, Germany.; Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Arkhypov I; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute at the University Medical Centre Mannheim, Mannheim, Germany.; Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Simon SCS; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany., Hetjens S; Department of Medical Statistics and Biomathematics, University Medical Center Mannheim, Medical Faculty Mannheim of the University of Heidelberg, Mannheim, Germany., Müller V; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany., Utikal J; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute at the University Medical Centre Mannheim, Mannheim, Germany.; Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Umansky V; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute at the University Medical Centre Mannheim, Mannheim, Germany.; Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

Publikováno v: Frontiers in immunology [Front Immunol] 2023 Feb 13; Vol. 14, pp. 1065767. Date of Electronic Publication: 2023 Feb 13 (Print Publication: 2023).

Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2.

Autor: Özbay Kurt FG; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany.; Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Lepper A; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany.; Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Gerhards C; Institute for Clinical Chemistry, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Roemer M; Institute for Clinical Chemistry, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Lasser S; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany.; Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Arkhypov I; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany.; Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Bitsch R; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany.; Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Bugert P; German Red Cross Blood Service Baden-Württemberg - Hessen, Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany., Altevogt P; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany.; Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Gouttefangeas C; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany., Neumaier M; Institute for Clinical Chemistry, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Utikal J; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany.; Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Umansky V; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany.; Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

Publikováno v: Frontiers in immunology [Front Immunol] 2022 Oct 12; Vol. 13, pp. 1012526. Date of Electronic Publication: 2022 Oct 12 (Print Publication: 2022).

The excretion and biological antioxidant activity of elderberry antioxidants in healthy humans

Autor: Netzel, M., Strass, G., Herbst, M., Dietrich, H., Bitsch, R., Bitsch, I., Frank, T.

Publikováno v: In Food Research International 2005 38(8):905-910